Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-023833
Filing Date
2022-11-09
Accepted
2022-11-09 16:07:53
Documents
56
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dice-20220930.htm   iXBRL 10-Q 3339775
2 EX-31.1 dice-ex31_1.htm EX-31.1 20536
3 EX-31.2 dice-ex31_2.htm EX-31.2 20250
4 EX-32.1 dice-ex32_1.htm EX-32.1 13389
5 EX-32.2 dice-ex32_2.htm EX-32.2 12781
  Complete submission text file 0000950170-22-023833.txt   8285431

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dice-20220930_def.xml EX-101.DEF 157275
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dice-20220930.xsd EX-101.SCH 41286
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dice-20220930_pre.xml EX-101.PRE 259344
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dice-20220930_lab.xml EX-101.LAB 366147
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dice-20220930_cal.xml EX-101.CAL 46433
50 EXTRACTED XBRL INSTANCE DOCUMENT dice-20220930_htm.xml XML 1179118
Mailing Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080
Business Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

EIN.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40794 | Film No.: 221372589
SIC: 2834 Pharmaceutical Preparations